

WHAT IS CLAIMED IS:

1. An antibody that is capable of binding a PF4AR polypeptide.
2. The antibody of claim 1 that does not cross-react with a receptor capable of binding another PF4 superfamily member.
3. The antibody of claim 1 wherein the PF4AR polypeptide is an IL-8 receptor.
4. The antibody of claim 3 wherein the PF4AR polypeptide is an IL-8 type A receptor.
5. The antibody of claim 4 that is a monoclonal antibody.
6. The antibody of claim 4 that has the isotype IgG1.
7. The antibody of claim 1 that neutralizes the activity of a PF4AR polypeptide.
8. The antibody of claim 4 that neutralizes the activity of an IL-8 type A receptor.
9. The antibody of claim 8 that is a monoclonal antibody designated 2A4, having ATCC Deposit No. 11377.
10. The antibody of claim 8 that is a monoclonal antibody designated 9H1, having ATCC Deposit No. 11376.
11. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

12. A composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.
13. A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.
14. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 11.
15. The method of claim 14 wherein the mammal is a human.
16. The method of claim 14 wherein the disorder is an inflammatory bowel disease or a chronic inflammation of the lung.
17. The method of claim 14 wherein the composition is administered systemically.
18. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 12.
19. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 13.